Caris Life Sciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-273.44	-281.89	-341.42	-320.83
Depreciation & Amortization	38.25	48.91	49	48.25
Other Amortization	7.41	7.05	5.38	2.65
Stock-Based Compensation	28.88	18.64	15.24	22.9
Other Operating Activities	10.86	-8.85	2.82	-16.43
Change in Accounts Receivable	-23.53	-33.82	-15.08	-11.91
Change in Inventory	3.5	5.46	-4.44	-11.1
Change in Accounts Payable	0.81	-0.23	7.17	8.91
Change in Other Net Operating Assets	4.65	-0.48	5.22	-8.16
Operating Cash Flow	-202.61	-245.2	-276.1	-285.71
Capital Expenditures	-9.4	-8.44	-22.32	-42.26
Investment in Securities	-	61.38	237.09	-240.73
Investing Cash Flow	-9.4	52.93	214.77	-282.99
Long-Term Debt Issued	-	199.98	191.31	-
Long-Term Debt Repaid	-	-0.16	-180.74	-0.96
Net Debt Issued (Repaid)	-0.1	199.82	10.57	-0.96
Issuance of Common Stock	2.75	1.53	1.87	11.41
Other Financing Activities	-1.16	-1.06	-2.3	-
Financing Cash Flow	1.47	200.29	10.13	10.45
Foreign Exchange Rate Adjustments	-0	-0	0.06	0
Net Cash Flow	-210.54	8.02	-51.13	-558.25
Free Cash Flow	-212.01	-253.64	-298.42	-327.96
Free Cash Flow Margin	-46.85%	-61.52%	-97.48%	-126.88%
Free Cash Flow Per Share	-1.49	-1.79	-2.13	-2.46
Cash Interest Paid	53.77	49.02	15.78	24.24
Levered Free Cash Flow	-	-143.65	-178.04	-
Unlevered Free Cash Flow	-	-119.44	-163.66	-
Change in Net Working Capital	-	17.85	5.87	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q